Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors
Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors
复制标题
DOI：
10.1023/a:1008334404825
复制
发表时间：
2000-08-01
影响因子：
50.5
通讯作者：
Goldhirsch, A
中科院分区：
文献类型：
--
作者：
Colleoni, M;Minchella, I;Goldhirsch, A
背景资料：我们最近证实，在绝经前雌激素受体（ER）缺失的肿瘤患者中，初次手术后早期开始全身化疗可能会改善预后。这些数据表明不表达激素受体的肿瘤对化疗的反应性不同。为了检验这一假设，我们评估了ER和孕激素受体（PgR）-缺乏tumors.Patients和方法：活检证实的T-2-T-3，N 0 -2乳腺癌患者术前化疗的反应在一个单一的机构从1995年1月至1999年8月与术前化疗进行了回顾性评价。ER和PgR进行了化学方法测定，并为此目的分为不存在（0%的细胞阳性）或阳性（大于或等于1%的细胞）。与ER和/或PgR阳性肿瘤患者相比，ER和PgR缺失患者的缓解率存在显著差异（82% vs. 57%，P = 0.03 Fisher精确检验）。病理完全缓解率也有显着差异，在两组（23%对7%，分别为P = 0.04）。结论：根据激素受体表达的不同程度的反应支持这一假设，即肿瘤不表达ER和PgR可能代表不同的临床实体化疗反应。
Background: We recently demonstrated that in premenopausal patients with estrogen receptors (ER)-absent tumors, early initiation of systemic chemotherapy after primary surgery might improve outcome. These data indicate a different responsiveness to chemotherapy for tumors not expressing hormone receptors. To test this hypothesis we evaluated the responsiveness to preoperative chemotherapy in patients with ER and progesterone receptors (PgR)-absent tumors.Patients and methods: Patients with biopsy-proven T-2-T-3, N0-2 breast cancer treated at a single institution from January 1995 to August 1999 with preoperative chemotherapy were retrospectively evaluated. ER and PgR were determined immunohistochemically and classified for this purpose as absent (0% of the cells positive) or positive (greater than or equal to 1% of the cells).Results: On 117 evaluable patients 72 had an objective response (61%). A significant difference in response was observed for patients with ER and PgR absent compared with those with ER and/or PgR-positive tumors (82% vs. 57%, P = 0.03 Fishers's exact test). Pathological complete remission rates were also significantly different in the two groups (23% vs. 7%, respectively; P = 0.04).Conclusions: The different degree of response according to hormone receptors expression supports the hypothesis that tumors not expressing both ER and PgR might represent a different clinical entity in terms of chemotherapy responsiveness.